Description
Emtricitabine moderately reduces hepatocyte proliferation independent of effects on mtDNA in HepG2 human hepatoma cells.
Synonyms
Emtricitabine; Coviracil; Emtriva; Racivir; (-)-FTC; W-201247; W-201248; E1007; 24229-EP2298783A1; 24229-EP2314590A1; AB01275429-01; 3B2-0188
IUPAC Name
4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one
Molecular Formula
C8H10FN3O3S
Canonical SMILES
C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F
InChI
InChI=1S/C8H10FN3O3S/c9-4-1-12(8(14)11-7(4)10)5-3-16-6(2-13)15-5/h1,5-6,13H,2-3H2,(H2,10,11,14)/t5-,6+/m0/s1
InChIKey
XQSPYNMVSIKCOC-NTSWFWBYSA-N
Boiling Point
443.3±55.0 °C at 760 mmHg
Flash Point
221.9±31.5 °C
Solubility
In Vitro:
DMSO: 10.8 mg/mL (43.68 mM; Need ultrasonic and warming)
In Vivo:
1.Emtricitabine (FTC) is prepare in vehicle (DMSO and 0.9% NaCl)
Appearance
White to off-white powder
Storage
Powder: -20°C: 3 years; 4°C: 2 years In solvent: -80°C: 6 months; -20°C: 1 month
Vapor Pressure
0.0±2.4 mmHg at 25°C